Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Recent Posts
View:
Post by CADInvestor12 on Jun 13, 2024 12:21pm

Recent Posts

I would read this board to try and get other investors opinions on earnings/ developments etc. Some have interesting perspectives, while others are completely clueless. I'm surprised with the recent opinions, frankly it proves that most of you have no idea what you're talking about. Yes, the share price is frustrating and the longer term growth catalysts are taking longer than expected but how can you not be impressed with the current exec team? The business has completely turned around, when Pidduck started TTM revenue was ~$21.1M & losing ~$48M (Q1/22 to Q2/21). Now TTM revenue is ~$37M & losing ~$13M and we're on the cusp of positive EBITDA + cash flow. Over the last 2 years revenue has almost doubled, while savings of ~$35M have been realized. With Medipharms existing infrastructure any M&A deal (even if they use equity) would be accretive and would create more value/ a better use of cash than a share buyback. For those spewing garbage about managements poor performance & advocating buybacks, give your head a shake and go invest in mutual funds. You don't belong here and have no idea what it takes to successfully grow/ turn a business around.
Comment by QContinuum1 on Jun 13, 2024 3:12pm
  agreed fully that existing executive management deserves kudos and not ire for turning this business around.  Where I disagree is that any form of M&A is beneficial and that a buyback would be less so.  Do honestly think that this business, even with its growth trajectory, could withstand the weight of further dilution in the short the medium term?   I don't mind ...more  
Comment by CADInvestor12 on Jun 13, 2024 5:18pm
I don't think M&A for the sake of M&A is the right approach but if the opportunity is accretive & the target company is a strategic fit (medical/ international/ even US?) then I would prefer that over a buyback. Once they are CFP, then I wouldn't be entirely opposed to a buyback. Honestly, to free up additional cash, I wouldn't be opposed to a sale & lease-back of their ...more  
Comment by QContinuum1 on Jun 13, 2024 7:32pm
  The reason I say buyback now is because of the claim that they are at the cusp of CFP.  So keep the enemies at the gate for now and wait a few more quarters before going carcass hunting.  They'll still be there when we're ready and if they're not, so be it, wasn't meant to be.  But certainly I'm ok with M&A, just not now.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities